busulfan has been researched along with Combined Immunodeficiency, X-Linked in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lentiviral vector gene therapy combined with low-exposure, targeted busulfan conditioning in infants with newly diagnosed SCID-X1 had low-grade acute toxic effects and resulted in multilineage engraftment of transduced cells, reconstitution of functional T cells and B cells, and normalization of NK-cell counts during a median follow-up of 16 months." | 2.90 | Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. ( Abdelsamed, H; Aldave Becerra, JC; Church, JA; Condori, J; Cowan, MJ; Cross, SJ; da Matta Ain, AC; De Ravin, SS; Dokmeci, E; Dowdy, J; Gottschalk, S; Janssen, W; Kang, G; Li, C; Lockey, T; Long-Boyle, JR; Love, JT; Ma, Z; Malech, HL; Mamcarz, E; Maron, G; Meagher, MM; Puck, JM; Ryu, BY; Sorrentino, BP; Tang, X; Triplett, B; van der Watt, H; Weiss, MJ; Youngblood, B; Zhou, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mamcarz, E | 1 |
| Zhou, S | 1 |
| Lockey, T | 1 |
| Abdelsamed, H | 1 |
| Cross, SJ | 1 |
| Kang, G | 1 |
| Ma, Z | 1 |
| Condori, J | 1 |
| Dowdy, J | 1 |
| Triplett, B | 1 |
| Li, C | 1 |
| Maron, G | 1 |
| Aldave Becerra, JC | 1 |
| Church, JA | 1 |
| Dokmeci, E | 1 |
| Love, JT | 1 |
| da Matta Ain, AC | 1 |
| van der Watt, H | 1 |
| Tang, X | 1 |
| Janssen, W | 1 |
| Ryu, BY | 1 |
| De Ravin, SS | 1 |
| Weiss, MJ | 1 |
| Youngblood, B | 1 |
| Long-Boyle, JR | 1 |
| Gottschalk, S | 1 |
| Meagher, MM | 1 |
| Malech, HL | 1 |
| Puck, JM | 1 |
| Cowan, MJ | 1 |
| Sorrentino, BP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells[NCT03538899] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2018-05-31 | Recruiting | ||
| Gene Therapy for X Linked Severe Combined Immunodeficiency[NCT04286815] | 10 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | |||
| A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells[NCT01512888] | Phase 1/Phase 2 | 28 participants (Anticipated) | Interventional | 2016-08-17 | Suspended (stopped due to voluntary hold) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for busulfan and Combined Immunodeficiency, X-Linked
| Article | Year |
|---|---|
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Topics: Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; Busulfan; Genetic Therapy; Genetic Vectors; | 2019 |
1 other study available for busulfan and Combined Immunodeficiency, X-Linked
| Article | Year |
|---|---|
New Gene Therapy Potential Cure for "Bubble Boy Disease": An experimental gene therapy has allowed children with SCID-1X to develop fully functioning immune systems.
Topics: Busulfan; Child; Child, Preschool; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Humans | 2019 |